What depemokimab is and how it works
Depemokimab, marketed under the brand name Exdensur and developed by GSK, is an engineered ultra-long-acting anti-IL-5 monoclonal antibody designed for the management of eosinophilic diseases. Its mechanism centres on neutralising interleukin-5 (IL-5), the key cytokine responsible for the proliferation, activation, and survival of eosinophils — the white blood cells whose dysregulated accumulation drives type 2 inflammatory conditions including severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
What separates depemokimab from its predecessors in the IL-5 inhibitor class is the molecular engineering applied to its Fc region. This Fc engineering extends the antibody’s half-life to a degree that supports a dosing interval of approximately 26 weeks — meaning patients require only two subcutaneous injections per year. In contrast, earlier-generation IL-5 pathway inhibitors such as mepolizumab require monthly administration, while benralizumab involves an initial monthly loading phase followed by bimonthly maintenance dosing.
Depemokimab (brand name Exdensur) is an anti-IL-5 monoclonal antibody developed by GSK with an engineered extended half-life that enables a twice-yearly (every 26-week) subcutaneous dosing regimen for eosinophilic diseases including severe asthma and CRSwNP.
The IL-5 pathway is a validated and commercially proven therapeutic target. According to data tracked by WHO, severe asthma affects hundreds of millions of people globally, with eosinophilic endotypes representing a significant and treatable subpopulation. The strategic importance of depemokimab lies not only in its mechanism but in the practical and commercial implications of its dosing architecture.
Interleukin-5 (IL-5) is a cytokine that drives the production, activation, and survival of eosinophils. In conditions such as severe eosinophilic asthma and CRSwNP, IL-5 is overexpressed, leading to pathological eosinophil accumulation in airways and nasal tissue. Blocking IL-5 reduces eosinophil counts and the associated inflammatory damage — the core rationale for the IL-5 inhibitor drug class.
The 26-week dosing advantage: how twice-yearly changes the calculus
Depemokimab’s twice-yearly dosing schedule represents a meaningful departure from the administration burden associated with existing biologics in the eosinophilic disease space. The 26-week interval — achieved through Fc region engineering that extends the antibody’s circulating half-life — reduces the number of clinic visits or home injections required from twelve or more per year (for monthly biologics) to just two.
“A twice-yearly subcutaneous dosing regimen distinguishes depemokimab from existing monthly or bimonthly IL-5/IL-5Rα inhibitors — a structural advantage with direct implications for patient adherence, healthcare resource use, and formulary positioning.”
For patients managing chronic conditions that require indefinite biologic therapy, the reduction in injection frequency carries tangible quality-of-life implications. Adherence to injectable biologics is known to decline with increasing administration frequency, as documented in respiratory medicine literature published by journals indexed in NIH PubMed. A twice-yearly regimen removes a substantial part of this friction.
From a payer and health system perspective, the reduction in administration visits associated with a twice-yearly biologic can translate into lower per-patient costs beyond the drug acquisition price itself. Infusion centre time, nursing resource, and patient travel costs are all reduced when administration frequency drops from monthly to biannual. This positions depemokimab favourably in formulary negotiations, particularly in health systems where total cost of care — rather than unit drug price alone — drives reimbursement decisions.
Explore the full patent and clinical landscape for depemokimab and the IL-5 inhibitor class with PatSnap Eureka.
Search IL-5 Inhibitor Patents in PatSnap Eureka →Competitive landscape: mepolizumab, benralizumab, and dupilumab
Depemokimab enters a market already shaped by three established biologics, each with distinct mechanisms, dosing schedules, and approved indications in the type 2 inflammation space. Understanding the competitive dynamics requires examining both the mechanistic differences and the commercial positioning of each agent.
Mepolizumab: the incumbent IL-5 inhibitor
Mepolizumab (Nucala), also developed by GSK, is an anti-IL-5 monoclonal antibody administered monthly by subcutaneous injection. It holds approvals across severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), and CRSwNP. Depemokimab’s arrival creates an unusual intra-company competitive dynamic: GSK must manage cannibalisation risk while positioning Exdensur as a next-generation option for patients seeking reduced injection frequency. The twice-yearly regimen is the primary differentiator that justifies the commercial transition.
Benralizumab: the IL-5Rα approach
Benralizumab targets the IL-5 receptor alpha (IL-5Rα) rather than IL-5 itself, enabling direct eosinophil depletion through antibody-dependent cellular cytotoxicity (ADCC). Its dosing involves monthly subcutaneous injections for the first three doses, followed by bimonthly maintenance — yielding approximately eight injections per year on stable therapy. Benralizumab holds approvals in severe eosinophilic asthma and has been investigated in CRSwNP. Against depemokimab’s twice-yearly schedule, benralizumab’s bimonthly maintenance remains a less convenient option for patients.
Dupilumab: the broad type 2 blocker
Dupilumab targets the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes, providing broader type 2 inflammation suppression than IL-5-specific agents. It is approved for severe asthma, CRSwNP, atopic dermatitis, eosinophilic oesophagitis, and prurigo nodularis — a breadth of indications that no IL-5-specific biologic currently matches. However, dupilumab requires biweekly subcutaneous administration, resulting in approximately 26 injections per year. Its broader mechanism is both a competitive strength (greater indication coverage) and a potential weakness (less targeted for purely eosinophilic endotypes). As noted in regulatory guidance published by the EMA, patient endotyping is increasingly central to biologic selection in severe asthma.
Depemokimab (Exdensur) competes directly with mepolizumab (monthly IL-5 inhibitor), benralizumab (bimonthly IL-5Rα inhibitor), and dupilumab (biweekly IL-4Rα/IL-13 blocker) in the type 2 inflammation biologic market, with its twice-yearly dosing schedule as the primary point of differentiation.
CRSwNP label expansion: the upper airway opportunity
Chronic rhinosinusitis with nasal polyps (CRSwNP) represents one of the most strategically important label expansions for depemokimab. CRSwNP is an eosinophilic inflammatory condition of the upper airways characterised by the same type 2 immune dysregulation — IL-5 overexpression, eosinophil accumulation, and tissue remodelling — that drives severe eosinophilic asthma in the lower airways. This biological continuity makes CRSwNP a natural and scientifically coherent expansion target for an anti-IL-5 biologic already approved in asthma.
CRSwNP and severe eosinophilic asthma are increasingly understood as manifestations of the same type 2 inflammatory continuum across the upper and lower airways. Patients with both conditions — a common comorbidity pattern — represent a high-value target population for biologics capable of addressing both indications simultaneously, a positioning that depemokimab’s CRSwNP expansion directly enables.
The CRSwNP biologic market is already contested. Dupilumab holds a strong position in CRSwNP, having been approved for this indication and demonstrating robust clinical outcomes in nasal polyp reduction and symptom control. Mepolizumab has also received CRSwNP approval, establishing the IL-5 pathway’s validity in the upper airway. Depemokimab’s CRSwNP label expansion, if approved, would allow GSK to offer a single twice-yearly biologic capable of addressing both severe asthma and CRSwNP — a meaningful proposition for the substantial proportion of patients with concurrent disease in both compartments.
Depemokimab is being investigated for chronic rhinosinusitis with nasal polyps (CRSwNP) as a label expansion beyond its primary severe asthma indication, targeting the type 2 inflammatory pathway shared between upper and lower airway eosinophilic disease.
The clinical and regulatory pathway for CRSwNP expansion in IL-5 biologics is well established, given that mepolizumab and dupilumab have already navigated it successfully. Regulatory agencies including the FDA have accepted nasal polyp score and nasal obstruction symptom score as validated endpoints for CRSwNP trials, providing a clear evidentiary framework for depemokimab’s expansion programme.
Track depemokimab’s CRSwNP clinical trial filings and patent applications in real time with PatSnap Eureka.
Monitor Depemokimab in PatSnap Eureka →IP strategy and the ultra-long-acting biologic race
Depemokimab’s commercial launch and CRSwNP expansion are inseparable from the broader intellectual property strategy surrounding ultra-long-acting biologics. The Fc engineering techniques that extend depemokimab’s half-life to 26 weeks are themselves the subject of patent protection, and the competitive race to develop next-generation extended-half-life antibodies is generating a substantial body of IP activity across the biopharmaceutical industry.
GSK’s research code for depemokimab — GSK3511294 — appears in clinical literature associated with the SWIFT programme and related eosinophilic disease trials. The molecule’s engineering distinguishes it from first-generation IL-5 inhibitors not only in its dosing architecture but in the proprietary molecular modifications that underpin it. Patent protection for Fc-engineered antibodies typically spans multiple claim categories: the modified antibody itself, the specific amino acid substitutions conferring extended half-life, the manufacturing process, and the methods of treatment for each approved indication.
The ultra-long-acting biologic concept is not unique to GSK. The broader pharmaceutical industry, as tracked by innovation databases including PatSnap‘s global patent intelligence platform, is investing significantly in Fc engineering, half-life extension technologies, and subcutaneous formulation improvements across multiple therapeutic areas. Depemokimab represents the leading clinical-stage realisation of this approach in the IL-5 inhibitor class, but the competitive IP landscape around extended-half-life antibody engineering is active and growing.
For IP professionals and R&D strategists monitoring this space, the key questions concern freedom-to-operate around Fc engineering platforms, the scope of GSK’s composition-of-matter claims for depemokimab, and the timeline of potential biosimilar entry once core patents expire. The EPO and USPTO patent databases, alongside proprietary analytics platforms, provide the most granular view of the evolving IP terrain surrounding this molecule and its competitors.
Depemokimab’s extended half-life is achieved through Fc region engineering of the anti-IL-5 antibody, a proprietary molecular modification that is itself subject to patent protection and represents a key area of IP activity in the ultra-long-acting biologic race. GSK’s research code for depemokimab is GSK3511294.